The stock has a 36-month beta value of 0.54. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for ATRA is 4.22M, and at present, short sellers hold a 12.89% of that float. On December 13, 2024, the average trading volume of ATRA was 105.31K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ATRA) stock’s latest price update
The stock price of Atara Biotherapeutics Inc (NASDAQ: ATRA) has plunged by -6.81 when compared to previous closing price of 11.75, but the company has seen a -12.47% decline in its stock price over the last five trading sessions. businesswire.com reported 2024-11-27 that THOUSAND OAKS, Calif.–(BUSINESS WIRE)—- $ATRA #CART–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 3:50 p.m. EST. A li.
ATRA’s Market Performance
Atara Biotherapeutics Inc (ATRA) has experienced a -12.47% fall in stock performance for the past week, with a -6.17% drop in the past month, and a 12.65% rise in the past quarter. The volatility ratio for the week is 7.80%, and the volatility levels for the past 30 days are at 9.88% for ATRA. The simple moving average for the last 20 days is -8.78% for ATRA stock, with a simple moving average of -8.54% for the last 200 days.
Analysts’ Opinion of ATRA
Many brokerage firms have already submitted their reports for ATRA stocks, with Mizuho repeating the rating for ATRA by listing it as a “Neutral.” The predicted price for ATRA in the upcoming period, according to Mizuho is $1 based on the research report published on November 09, 2023 of the previous year 2023.
ATRA Trading at 5.40% from the 50-Day Moving Average
After a stumble in the market that brought ATRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.28% of loss for the given period.
Volatility was left at 9.88%, however, over the last 30 days, the volatility rate increased by 7.80%, as shares sank -23.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.89% upper at present.
During the last 5 trading sessions, ATRA fell by -12.47%, which changed the moving average for the period of 200-days by -42.41% in comparison to the 20-day moving average, which settled at $12.00. In addition, Atara Biotherapeutics Inc saw -14.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATRA starting from Henrich Jill, who sale 1,000 shares at the price of $11.20 back on Nov 18 ’24. After this action, Henrich Jill now owns 19,378 shares of Atara Biotherapeutics Inc, valued at $11,198 using the latest closing price.
Hyllengren Eric J, the EVP, CFO and COO of Atara Biotherapeutics Inc, sale 1,364 shares at $11.20 during a trade that took place back on Nov 18 ’24, which means that Hyllengren Eric J is holding 23,392 shares at $15,274 based on the most recent closing price.
Stock Fundamentals for ATRA
Current profitability levels for the company are sitting at:
- -1.19 for the present operating margin
- 0.83 for the gross margin
The net margin for Atara Biotherapeutics Inc stands at -9.59. The total capital return value is set at 9.02. Equity return is now at value -2014.86, with -80.34 for asset returns.
Currently, EBITDA for the company is -266.0 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 0.66. The receivables turnover for the company is 75.24for trailing twelve months and the total asset turnover is 0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.59.
Conclusion
To sum up, Atara Biotherapeutics Inc (ATRA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
